Eprinomectin (Eprinex, LongRange)

Eprinomectin is a second-generation avermectin antiparasitic agent specifically developed to address the unique needs of dairy cattle production while maintaining the broad-spectrum efficacy characteristic of the macrocyclic lactone drug class. Marketed primarily under the brand names Eprinex and LongRange, eprinomectin represents a significant pharmaceutical advancement by offering a zero-day milk withdrawal period for the pour-on formulation, making it the only macrocyclic lactone approved for use in lactating dairy cattle whose milk is intended for human consumption. This unique property has established eprinomectin as an indispensable tool in dairy cattle health management, filling a critical gap that other avermectins and milbemycins could not address.

The mechanism of action of eprinomectin follows the same fundamental pharmacology as other macrocyclic lactones, involving selective and high-affinity binding to glutamate-gated chloride ion channels present in invertebrate nerve and muscle cells. This binding causes an irreversible increase in chloride ion permeability, leading to hyperpolarization of the affected cells, subsequent paralysis, and death of the target parasites. The specificity of this mechanism for invertebrate physiology accounts for the excellent safety margin in mammalian hosts, including cattle. What distinguishes eprinomectin from other avermectins is its unique pharmacokinetic profile, particularly its low partitioning into milk, which allows for the zero-day milk withdrawal that defines its commercial utility.

The pour-on formulation of eprinomectin is available as a ready-to-use topical solution containing 5 mg of eprinomectin per milliliter, designed for application along the backline of cattle. The formulation vehicle has been optimized to ensure consistent transdermal absorption while minimizing excretion into milk. Following topical application, eprinomectin achieves systemic distribution, reaching therapeutic concentrations in tissues where internal parasites reside while simultaneously providing effective concentrations at the skin surface for control of external parasites. The LongRange formulation represents an extended-release injectable version that provides persistent activity against internal parasites for up to 150 days.

From a regulatory perspective, eprinomectin pour-on holds a distinctive position as the only topical endectocide with FDA approval for use in lactating dairy cattle with a zero-day milk discard requirement. This approval reflects extensive pharmacokinetic and residue depletion studies demonstrating that milk from treated cows does not contain drug residues exceeding established tolerances at any time post-treatment. The product maintains over-the-counter status for the pour-on formulation, allowing dairy producers to incorporate eprinomectin into routine parasite control programs without veterinary prescription while still benefiting from veterinary consultation for optimal program design. The meat withdrawal period must still be observed, making treatment timing an important consideration for cull dairy animals.

Eprinomectin pour-on is indicated for the treatment and control of an extensive range of internal and external parasites affecting beef and dairy cattle, with its primary distinguishing feature being approval for use in lactating dairy cattle whose milk is sold for human consumption. The labeled indications encompass gastrointestinal roundworms, lungworms, cattle grubs, sucking and biting lice, and mange mites, providing comprehensive parasite control through a single convenient topical application. This broad spectrum of activity addresses the most economically significant parasites challenging cattle productivity across both beef and dairy production systems.

Gastrointestinal nematode control represents a primary indication for eprinomectin, with demonstrated efficacy against adult and immature stages of major pathogenic species. The drug effectively controls Ostertagia ostertagi (brown stomach worm) including inhibited fourth-stage larvae, Haemonchus placei (barber pole worm), Trichostrongylus axei, Cooperia species, Bunostomum phlebotomum (hookworm), Oesophagostomum radiatum (nodular worm), Nematodirus helvetianus, and Trichuris species (whipworms). Control of these parasites is essential for maintaining milk production, growth rates, and feed efficiency in both dairy and beef operations. Eprinomectin also provides effective treatment of Dictyocaulus viviparus, the bovine lungworm that causes significant respiratory disease and production losses.

For dairy operations specifically, eprinomectin addresses a long-standing challenge in managing parasites in lactating cows without sacrificing milk production or incurring economic losses from discarded milk. Prior to eprinomectin's approval, dairy producers faced the difficult choice between leaving lactating cows untreated, accepting production losses and welfare concerns from parasite burdens, or treating with other macrocyclic lactones and discarding milk for extended periods. Eprinomectin's zero-day milk withdrawal allows treatment decisions to be based solely on parasitological need without economic penalties from lost milk sales.

External parasite control indications include all developmental stages of cattle grubs (Hypoderma bovis and Hypoderma lineatum), which cause significant economic losses through hide damage, reduced weight gains, and the behavioral disturbance known as gadding. Eprinomectin effectively controls sucking lice species (Linognathus vituli, Haematopinus eurysternus, and Solenopotes capillatus) and biting lice (Bovicola bovis), which can reach economically damaging levels particularly during winter housing periods when animal-to-animal contact facilitates transmission. Mange mite infestations caused by Sarcoptes scabiei, Psoroptes ovis, and Chorioptes bovis also respond to eprinomectin treatment.

The extended-release injectable formulation (LongRange) expands the utility of eprinomectin by providing persistent protection against internal parasites for up to 100-150 days, depending on the specific parasite species. This extended activity is particularly valuable for grazing cattle that experience continuous exposure to pasture-borne parasites, reducing the need for multiple treatments during the grazing season. The LongRange formulation is approved for beef cattle and non-lactating dairy cattle but carries different withdrawal requirements and prescription status compared to the pour-on formulation.

The recommended dosage of eprinomectin pour-on for cattle is 500 micrograms per kilogram of body weight (500 mcg/kg), corresponding to 1 milliliter of the 5 mg/mL formulation per 10 kilograms of body weight. In practical terms, this equals 1 mL per 22 pounds of body weight. Accurate determination of body weight through weighing or careful estimation is essential for proper dosing, as underdosing may result in treatment failure and contribute to anthelmintic resistance development, while significant overdosing wastes product and may theoretically increase the risk of adverse effects. When treating groups of similarly sized cattle, dosing should be calculated based on the heaviest animal in the group to ensure all animals receive adequate treatment.

Administration of eprinomectin pour-on involves applying the calculated dose as a continuous stream along the backline of the animal from the withers to the tailhead. The applicator should be positioned to part the hair and deliver the product directly onto the skin surface rather than merely onto the hair coat, as skin contact is necessary for optimal absorption. The application should form a single continuous strip rather than discrete spots, ensuring even distribution along the dorsal midline. Proper restraint of animals during application is important for accurate dosing and operator safety, though the pour-on administration route is generally less stressful than injectable alternatives.

Treatment timing requires consideration of both production schedules and parasite biology. For dairy cattle, the zero-day milk withdrawal allows treatment at any time during lactation without economic loss from discarded milk, but the meat withdrawal period of 48 days must be observed for any treated animals intended for slaughter. This means that cull dairy cows and any treated animals moving to beef production must be held for the required period following the last treatment. Planning treatment timing around anticipated culling decisions helps avoid delays in marketing treated animals.

For cattle grub control, treatment should be administered after the heel fly season concludes but before migrating larvae reach critical anatomical locations in the esophageal wall or spinal canal. In most North American regions, optimal treatment timing falls between September and November, though specific recommendations vary by geographic location. Your veterinarian can provide guidance on appropriate timing based on local Hypoderma epidemiology. Treating during active larval migration through sensitive areas may result in host-parasite reactions when dying larvae release inflammatory substances.

Application technique significantly affects treatment success. Animals should be dry at the time of treatment, and if rain occurs within 24 hours of application, the treatment may need to be repeated as absorption may be incomplete. The applicator gun should be calibrated before use and checked periodically for accuracy throughout the treatment session. Multi-dose containers should be handled to prevent contamination, and unused product should be properly stored for future use within the labeled shelf life.

The meat withdrawal period for eprinomectin pour-on is 48 days in the United States for beef cattle. Dairy cattle treated with the pour-on formulation have no milk withdrawal requirement, making this product unique among macrocyclic lactone antiparasitics. However, treated dairy animals still require observation of the 48-day meat withdrawal if they are to be slaughtered for human consumption. Detailed treatment records including date, animals treated, product used, and dosage should be maintained to ensure compliance with withdrawal requirements and for farm management purposes.

Eprinomectin pour-on demonstrates excellent tolerability in cattle, with a well-established safety profile developed through extensive clinical trials and years of widespread commercial use in both beef and dairy populations. The vast majority of treated animals experience no observable adverse effects, and the product is considered one of the safest options for parasite control in lactating dairy cattle. However, awareness of potential side effects allows producers and veterinarians to monitor treated animals appropriately and respond to any adverse events that may occur.

The most commonly reported side effect of eprinomectin pour-on application is transient local reaction at the application site along the backline. This may manifest as mild redness of the skin, temporary hair discoloration or matting at the application site, or minor irritation that causes brief behavioral changes such as skin twitching or restlessness during and immediately after application. These local effects are typically self-limiting, resolving within hours to days without intervention, and rarely cause significant distress to treated animals. The pour-on vehicle is formulated to minimize irritation while maintaining effective transdermal penetration.

Systemic adverse effects from eprinomectin are uncommon at recommended doses and generally limited to animals with unusual sensitivity or those that receive significant overdoses. Signs of toxicity may include ataxia or unsteady gait, tremors, depression, excessive salivation, recumbency, and in severe cases, coma. These neurological signs reflect the mechanism of action of macrocyclic lactones when they reach toxic concentrations affecting the mammalian central nervous system. The wide therapeutic index of eprinomectin in cattle means that toxic effects are rare under normal use conditions, with safety studies demonstrating tolerance of doses several times higher than the therapeutic dose.

Host-parasite reactions following treatment of cattle with heavy burdens of certain parasites may occur and should not be confused with direct drug toxicity. When large numbers of parasites die simultaneously, the release of parasite antigens can trigger inflammatory responses. This phenomenon is particularly relevant during the treatment of cattle grub infestations when Hypoderma larvae die in sensitive anatomical locations. Larvae dying in the esophageal wall may cause swelling that interferes with swallowing or may cause bloat. More seriously, larvae dying in the epidural space around the spinal cord can cause posterior paralysis, incoordination, and recumbency. These reactions are preventable by proper treatment timing before larvae reach critical locations.

Productivity effects of eprinomectin treatment are overwhelmingly positive, with treated dairy cattle typically showing improved milk production as parasite burdens are eliminated. Occasional reports of temporary decreases in milk production following treatment may reflect the stress of handling and restraint rather than direct drug effects. Similarly, appetite and behavior generally improve as parasites are eliminated, though brief appetite reduction may occur in some animals immediately following treatment. Overall, the benefit-to-risk ratio of eprinomectin pour-on in dairy cattle strongly favors treatment for parasite control.

Despite its favorable safety profile and broad approval for use in dairy cattle, eprinomectin pour-on carries specific contraindications that must be respected to ensure animal safety and regulatory compliance. Understanding these contraindications allows producers and veterinarians to make appropriate treatment decisions and avoid situations where product use could result in adverse outcomes or violation of food safety regulations.

Hypersensitivity to eprinomectin or other macrocyclic lactone compounds represents a contraindication to product use. While true allergic reactions to avermectins are rare in cattle, any animal that has demonstrated a previous adverse reaction to eprinomectin, ivermectin, doramectin, moxidectin, or related compounds should not receive further treatment with products of this class without careful veterinary evaluation. Signs of hypersensitivity might include urticaria, angioedema, respiratory distress, or anaphylaxis, though such reactions are extremely uncommon in cattle.

Age restrictions apply to eprinomectin pour-on, with the product not recommended for use in very young calves. While specific minimum age requirements may vary by product labeling and regulatory jurisdiction, the developing nervous system and different pharmacokinetic parameters in neonatal animals may alter the safety profile. Consultation with a veterinarian is recommended before treating very young calves. Veal calves present additional considerations related to meat withdrawal times and production schedules that may limit practical use of this product.

Timing restrictions for cattle grub treatment represent a critical consideration that significantly affects the safety of eprinomectin use. Treatment should be avoided during periods when Hypoderma larvae are migrating through the esophageal wall or epidural space around the spinal cord. Killing larvae in these locations can trigger severe inflammatory reactions including esophageal edema, bloat, difficulty swallowing, posterior paralysis, and recumbency. In most North American regions, this critical period spans roughly from December through March, though exact timing varies by geographic location and climate. Animals recently imported from other regions may have different grub migration timelines requiring individual assessment.

While eprinomectin pour-on is approved for lactating dairy cattle with zero milk withdrawal, the meat withdrawal period of 48 days must be strictly observed for any animals intended for slaughter. Treatment of cull dairy cows or other animals close to their slaughter date requires careful planning to ensure the withdrawal period can be observed. Additionally, while the extended-release injectable formulation (LongRange) contains the same active ingredient, it has different contraindications and withdrawal requirements, including prohibition of use in lactating dairy cattle, and should not be confused with the pour-on product in terms of appropriate use.

Drug interaction considerations for eprinomectin pour-on parallel those of other macrocyclic lactone antiparasitics, with certain combinations requiring caution to avoid potential adverse outcomes. While eprinomectin demonstrates a relatively favorable drug interaction profile, understanding potential interactions helps ensure safe and effective use within comprehensive cattle health management programs.

Concurrent administration of multiple macrocyclic lactone products should be avoided due to the potential for additive pharmacological effects and toxicity. Using eprinomectin pour-on simultaneously with injectable avermectins, oral macrocyclic lactones, or other endectocide pour-on products may result in excessive systemic drug concentrations that could increase the risk of neurological adverse effects. When changing between macrocyclic lactone products, sufficient time should elapse to allow substantial elimination of the first product before administering another. This consideration is particularly important in operations using different products at various management stages throughout the year.

P-glycoprotein (P-gp) represents an important efflux transporter that limits macrocyclic lactone entry into the central nervous system, contributing to the safety margin of these drugs in mammals. Compounds that inhibit P-glycoprotein function could theoretically increase brain concentrations of eprinomectin and potentially enhance toxicity. While specific drug interaction studies in cattle are limited, known P-gp inhibitors in other species include certain antifungal agents, calcium channel blockers, and immunosuppressive drugs. Concurrent use of such compounds with eprinomectin should be approached with caution, particularly when treating animals at higher doses or with pre-existing conditions that might affect drug disposition.

Interactions with routine dairy cattle medications have not been extensively studied, but general pharmacological principles suggest several areas for consideration. Drugs affecting hepatic metabolism could theoretically alter eprinomectin elimination, though clinically significant interactions of this type have not been reported. Vaccines can generally be administered at the same time as eprinomectin treatment without concern for interaction, as the mechanisms are completely distinct. However, some practitioners prefer to separate parasite treatment from vaccination by several days to facilitate attribution of any adverse reactions to the responsible product. Concurrent use with other topical products should be avoided or carefully timed to prevent physical interference with eprinomectin absorption through the skin.

Comprehensive precautions during handling and administration of eprinomectin pour-on protect human health, ensure animal safety, maintain food safety standards, and support environmental responsibility. Personnel working with this product should understand potential hazards and implement appropriate safety measures throughout storage, preparation, and application processes.

Human safety precautions are essential when working with eprinomectin pour-on. Operators should wear appropriate personal protective equipment including chemical-resistant gloves, long-sleeved clothing, and eye protection during product handling and application. The pour-on formulation is designed for transdermal absorption in cattle and could similarly penetrate human skin, making direct contact avoidance important. If skin contact occurs, the affected area should be washed immediately and thoroughly with soap and water. Eye exposure requires prolonged flushing with clean water and medical attention if irritation persists. Persons with known hypersensitivity to avermectins should avoid handling these products.

Food safety compliance requires strict attention to withdrawal periods and use conditions despite the favorable zero-day milk withdrawal for the pour-on formulation. The 48-day meat withdrawal period must be observed without exception, requiring careful record-keeping and animal identification systems to ensure treated animals are not marketed before the withdrawal period expires. While milk from treated cows requires no discard period, producers should maintain treatment records that document compliance with approved use conditions. The extended-release injectable formulation (LongRange) has substantially different requirements including a much longer meat withdrawal and prohibition of use in dairy cattle, requiring clear differentiation between products.

Environmental considerations reflect the ecotoxicity of avermectin compounds, particularly to aquatic organisms and dung-dwelling invertebrates. Eprinomectin excreted in feces retains biological activity and can affect beneficial dung beetle populations that play important ecological roles in pasture ecosystems. Aquatic invertebrates are highly sensitive to avermectins, so treated cattle should not have direct access to streams, ponds, or other waterways immediately following treatment, and care should be taken to prevent runoff of product during or after application. Proper disposal of empty containers following label instructions minimizes environmental contamination.

Anthelmintic resistance management represents an increasingly important consideration as resistance to macrocyclic lactones has been documented in cattle nematode populations in various regions. To preserve the efficacy of eprinomectin and related products, treatment should be based on evidence of parasite burden rather than routine calendar-based protocols. Fecal egg count monitoring helps identify when treatment is necessary and can detect emerging resistance through post-treatment efficacy checks. Refugia-based strategies that maintain drug-susceptible parasite populations help slow resistance development. Consultation with a veterinarian experienced in parasitology can optimize treatment programs for both efficacy and sustainability.

Proper storage and handling of eprinomectin pour-on maintains product quality and efficacy while ensuring safety for personnel and the environment. The product should be stored at controlled room temperature, typically between 59°F and 86°F (15°C to 30°C), protected from light and extreme temperature fluctuations. The original container should be used for storage with the cap tightly secured between uses. Freezing should be avoided as it may alter formulation characteristics. The storage location should be secure from access by children, unauthorized personnel, and animals, preferably in a locked medication storage area.

Handling procedures should minimize contamination and human exposure. Before each use, the product should be visually inspected for any signs of deterioration such as color changes, precipitation, or particulate matter that might indicate degradation. The applicator system should be calibrated according to manufacturer specifications before treating animals and checked periodically throughout treatment sessions for continued accuracy. When using multi-dose containers, care should be taken to prevent contamination of the product by not allowing the applicator tip to contact animal hide, manure, or other potential contamination sources. Unused product should be returned to proper storage conditions promptly after treatment sessions.

Disposal procedures for empty containers and unused product must comply with local, state, and federal regulations governing veterinary pharmaceutical waste. Empty containers should be triple-rinsed with water before disposal, with rinse water disposed of according to local agricultural chemical waste guidelines. Containers must not be reused for any purpose including storage of water, feed, or other materials, as residual product could contaminate contents. Unused or expired product should be disposed of through approved pharmaceutical waste programs or returned to the manufacturer rather than being discarded in regular trash or poured down drains. The environmental persistence of avermectins and their toxicity to aquatic organisms make proper disposal particularly important for environmental protection.

Eprinomectin pour-on is broadly applicable across cattle breeds without specific breed-related contraindications, but understanding how breed characteristics, production systems, and animal types may influence treatment decisions can optimize outcomes. The pharmacokinetics and safety of eprinomectin have been evaluated across diverse cattle populations, generally demonstrating consistent efficacy and tolerability. However, certain breed-related factors warrant consideration in treatment planning.

Dairy breed considerations are particularly relevant given eprinomectin's unique position as the only macrocyclic lactone pour-on approved for lactating dairy cattle. Holstein, Jersey, Brown Swiss, Guernsey, Ayrshire, and other dairy breeds can all benefit from eprinomectin treatment during lactation without milk loss. High-producing dairy cattle may show measurable improvements in milk production following successful treatment of subclinical parasite burdens, as the metabolic demands of parasitism compete with lactation for nutrient resources. The stress of handling for treatment should be considered in high-producing cattle, and calm, efficient treatment procedures minimize any temporary production disruption.

Beef breeds including British breeds (Angus, Hereford, Shorthorn), Continental breeds (Charolais, Limousin, Simmental), Brahman-influenced cattle, and various crossbred combinations generally respond similarly to eprinomectin treatment. Hair coat characteristics vary among breeds, with some breeds having thicker or woollier coats that require more attention to ensure pour-on product reaches the skin surface. The formulation is designed for consistent absorption across coat types, but ensuring direct skin contact during application remains important regardless of breed. Brahman and Brahman-cross cattle may show different pharmacokinetic profiles for some drugs due to breed-related variations in metabolism, though this has not been identified as clinically significant for eprinomectin.

Dual-purpose breeds and crossbred cattle used in both dairy and beef production systems can utilize eprinomectin with attention to the intended endpoint. Animals in dairy production benefit from the zero-day milk withdrawal, while animals transitioning to beef production must observe the meat withdrawal period. Body condition, weight, and overall health status are more important than specific breed designation for treatment decisions, with thin or debilitated animals potentially showing enhanced sensitivity to medications and requiring more conservative approaches.

Eprinomectin pour-on belongs to the macrocyclic lactone class of antiparasitics with several related products offering alternative options for cattle parasite control. Understanding the relationships between these products helps inform treatment decisions based on factors including spectrum of activity, withdrawal requirements, convenience, cost, and resistance management considerations.

Within the macrocyclic lactone class, related pour-on products include ivermectin pour-on (Ivomec Pour-On), doramectin pour-on (Dectomax Pour-On), and moxidectin pour-on (Cydectin Pour-On). Each provides similar broad-spectrum efficacy against internal and external parasites with somewhat different characteristics. Ivermectin is the original avermectin pour-on, widely available and cost-effective but with milk withdrawal requirements that preclude use in lactating dairy cattle. Doramectin offers similar efficacy to ivermectin with a different pharmacokinetic profile. Moxidectin, a milbemycin rather than avermectin, may retain efficacy against some populations resistant to avermectins and has extended persistent activity against certain parasites.

The eprinomectin extended-release injectable formulation (LongRange) deserves mention as a related product that provides fundamentally different treatment characteristics. While containing the same active ingredient, LongRange offers persistent efficacy against internal parasites for up to 100-150 days, substantially reducing the need for retreatment during the grazing season. However, this formulation is approved only for beef cattle and non-lactating dairy cattle, has a 48-day meat withdrawal for beef cattle (121 days for dairy cattle), and requires veterinary prescription. It should not be confused with the pour-on formulation in terms of approved uses.

For producers seeking alternatives outside the macrocyclic lactone class, options include benzimidazole anthelmintics (fenbendazole, albendazole), levamisole, and combination products. These alternatives have different mechanisms of action and can be valuable components of resistance management programs utilizing rotation or combination strategies. However, none of these alternatives offer the combined internal and external parasite control of macrocyclic lactones, and separate treatments may be needed for ectoparasite control when using these alternative dewormers.